Antiplatelet and anticoagulant use after myocardial infarction

@article{Almony1996AntiplateletAA,
  title={Antiplatelet and anticoagulant use after myocardial infarction},
  author={G. T. Almony and J. Lefkovits and E. Topol},
  journal={Clinical Cardiology},
  year={1996},
  volume={19}
}
Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic… Expand
View on Wiley
onlinelibrary.wiley.com
23 Citations
Highly Influential Citations
1
Background Citations
6

23 Citations

Citation Type

Citation Type

Unmet therapeutic needs in the management of acute ischemia.
  • H. White
  • Medicine
  • The American journal of cardiology
  • 1997
  • 21
Glycoprotein IIb/IIIa receptor and its inhibition: A platelet-directed therapeutic strategy
  • 7
  • PDF
Trials of glycoprotein IIb‐IIIa inhibitors in non‐st‐segment elevation acute coronary syndromes: Applicability to the practice of medicine in the united states
  • 8
Pharmacologic therapies after myocardial infarction.
  • 20
Update on acute coronary syndromes and implications for therapy
  • G. Brogan
  • Medicine
  • Expert opinion on investigational drugs
  • 2003
  • 3
  • Highly Influenced
Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
  • 89
Clinical pharmacology of eptifibatide.
  • 210
  • PDF
Role of Clopidogrel in Unstable Angina and Non—ST‐Segment Elevation Myocardial Infarction: From Literature and Guidelines to Practice
  • 2
Bench to bedside: pathophysiology of acute coronary syndromes and implications for therapy.
  • G. Brogan
  • Medicine
  • Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
  • 2002
  • 14
The low‐molecular‐weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study
  • 47
...
1
2
3
...

References

SHOWING 1-10 OF 89 REFERENCES
Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.
  • 10
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
  • 175
Aspirin as an antiplatelet drug.
  • C. Patrono
  • Medicine
  • The New England journal of medicine
  • 1994
  • 900
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty
  • 72
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
  • 2,480
Selective thrombin inhibitors: the next generation of anticoagulants.
  • 22
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
  • 78
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
  • 314
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
  • 157
  • PDF
Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
  • 115
...
1
2
3
4
5
...